Cargando…

Magnolol Suppresses Pancreatic Cancer Development In Vivo and In Vitro via Negatively Regulating TGF-β/Smad Signaling

Magnolol, a hydroxylated biphenyl extracted from Magnolia officinalis, has recently drawn attention due to its anticancer potential. The present study was aimed to explore the effects of Magnolol on restraining the proliferation, migration and invasion of pancreatic cancer in vivo and in vitro. Magn...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Shuo, Shen, Jiaqi, Zhao, Jing, Wang, Jiazhong, Shan, Tao, Li, Junhui, Xu, Meng, Chen, Xi, Liu, Yang, Cao, Gang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7738609/
https://www.ncbi.nlm.nih.gov/pubmed/33344246
http://dx.doi.org/10.3389/fonc.2020.597672
_version_ 1783623154626723840
author Chen, Shuo
Shen, Jiaqi
Zhao, Jing
Wang, Jiazhong
Shan, Tao
Li, Junhui
Xu, Meng
Chen, Xi
Liu, Yang
Cao, Gang
author_facet Chen, Shuo
Shen, Jiaqi
Zhao, Jing
Wang, Jiazhong
Shan, Tao
Li, Junhui
Xu, Meng
Chen, Xi
Liu, Yang
Cao, Gang
author_sort Chen, Shuo
collection PubMed
description Magnolol, a hydroxylated biphenyl extracted from Magnolia officinalis, has recently drawn attention due to its anticancer potential. The present study was aimed to explore the effects of Magnolol on restraining the proliferation, migration and invasion of pancreatic cancer in vivo and in vitro. Magnolol showed significant anti-growth effect in an orthotopic xenograft nude mouse model, and immunohistochemical staining of the xenografts revealed that Magnolol suppressed vimentin expression and facilitated E-cadherin expression. The cytoactive detection using CCK-8 assay showed Magnolol inhibited PANC-1 and AsPC-1 concentration-dependently. Scratch healing assay and the Transwell invasion assay proved the inhibiting effects of Magnolol on cellular migration and invasion at a non-cytotoxic concentration. Western blot and rt-PCR showed that Magnolol suppressed epithelial-mesenchymal-transition by increasing the expression level of E-cadherin and decreasing those of N-cadherin and vimentin. Magnolol suppressed the TGF-β/Smad pathway by negatively regulating phosphorylation of Smad2/3. Moreover, TGF-β1 impaired the antitumor effects of Magnolol in vivo. These results demonstrated that Magnolol can inhibit proliferation, migration and invasion in vivo and in vitro by suppressing the TGF-β signal pathway and EMT. Magnolol could be a hopeful therapeutic drug for pancreatic malignancy.
format Online
Article
Text
id pubmed-7738609
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-77386092020-12-17 Magnolol Suppresses Pancreatic Cancer Development In Vivo and In Vitro via Negatively Regulating TGF-β/Smad Signaling Chen, Shuo Shen, Jiaqi Zhao, Jing Wang, Jiazhong Shan, Tao Li, Junhui Xu, Meng Chen, Xi Liu, Yang Cao, Gang Front Oncol Oncology Magnolol, a hydroxylated biphenyl extracted from Magnolia officinalis, has recently drawn attention due to its anticancer potential. The present study was aimed to explore the effects of Magnolol on restraining the proliferation, migration and invasion of pancreatic cancer in vivo and in vitro. Magnolol showed significant anti-growth effect in an orthotopic xenograft nude mouse model, and immunohistochemical staining of the xenografts revealed that Magnolol suppressed vimentin expression and facilitated E-cadherin expression. The cytoactive detection using CCK-8 assay showed Magnolol inhibited PANC-1 and AsPC-1 concentration-dependently. Scratch healing assay and the Transwell invasion assay proved the inhibiting effects of Magnolol on cellular migration and invasion at a non-cytotoxic concentration. Western blot and rt-PCR showed that Magnolol suppressed epithelial-mesenchymal-transition by increasing the expression level of E-cadherin and decreasing those of N-cadherin and vimentin. Magnolol suppressed the TGF-β/Smad pathway by negatively regulating phosphorylation of Smad2/3. Moreover, TGF-β1 impaired the antitumor effects of Magnolol in vivo. These results demonstrated that Magnolol can inhibit proliferation, migration and invasion in vivo and in vitro by suppressing the TGF-β signal pathway and EMT. Magnolol could be a hopeful therapeutic drug for pancreatic malignancy. Frontiers Media S.A. 2020-12-02 /pmc/articles/PMC7738609/ /pubmed/33344246 http://dx.doi.org/10.3389/fonc.2020.597672 Text en Copyright © 2020 Chen, Shen, Zhao, Wang, Shan, Li, Xu, Chen, Liu and Cao http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Chen, Shuo
Shen, Jiaqi
Zhao, Jing
Wang, Jiazhong
Shan, Tao
Li, Junhui
Xu, Meng
Chen, Xi
Liu, Yang
Cao, Gang
Magnolol Suppresses Pancreatic Cancer Development In Vivo and In Vitro via Negatively Regulating TGF-β/Smad Signaling
title Magnolol Suppresses Pancreatic Cancer Development In Vivo and In Vitro via Negatively Regulating TGF-β/Smad Signaling
title_full Magnolol Suppresses Pancreatic Cancer Development In Vivo and In Vitro via Negatively Regulating TGF-β/Smad Signaling
title_fullStr Magnolol Suppresses Pancreatic Cancer Development In Vivo and In Vitro via Negatively Regulating TGF-β/Smad Signaling
title_full_unstemmed Magnolol Suppresses Pancreatic Cancer Development In Vivo and In Vitro via Negatively Regulating TGF-β/Smad Signaling
title_short Magnolol Suppresses Pancreatic Cancer Development In Vivo and In Vitro via Negatively Regulating TGF-β/Smad Signaling
title_sort magnolol suppresses pancreatic cancer development in vivo and in vitro via negatively regulating tgf-β/smad signaling
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7738609/
https://www.ncbi.nlm.nih.gov/pubmed/33344246
http://dx.doi.org/10.3389/fonc.2020.597672
work_keys_str_mv AT chenshuo magnololsuppressespancreaticcancerdevelopmentinvivoandinvitrovianegativelyregulatingtgfbsmadsignaling
AT shenjiaqi magnololsuppressespancreaticcancerdevelopmentinvivoandinvitrovianegativelyregulatingtgfbsmadsignaling
AT zhaojing magnololsuppressespancreaticcancerdevelopmentinvivoandinvitrovianegativelyregulatingtgfbsmadsignaling
AT wangjiazhong magnololsuppressespancreaticcancerdevelopmentinvivoandinvitrovianegativelyregulatingtgfbsmadsignaling
AT shantao magnololsuppressespancreaticcancerdevelopmentinvivoandinvitrovianegativelyregulatingtgfbsmadsignaling
AT lijunhui magnololsuppressespancreaticcancerdevelopmentinvivoandinvitrovianegativelyregulatingtgfbsmadsignaling
AT xumeng magnololsuppressespancreaticcancerdevelopmentinvivoandinvitrovianegativelyregulatingtgfbsmadsignaling
AT chenxi magnololsuppressespancreaticcancerdevelopmentinvivoandinvitrovianegativelyregulatingtgfbsmadsignaling
AT liuyang magnololsuppressespancreaticcancerdevelopmentinvivoandinvitrovianegativelyregulatingtgfbsmadsignaling
AT caogang magnololsuppressespancreaticcancerdevelopmentinvivoandinvitrovianegativelyregulatingtgfbsmadsignaling